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Introduction. Primary cardiac sarcoma (PCS) has a poor prognosis compared to other sarcomas due to late presentation, challenging
resection, incidence of metastases, and limited efficacy of systemic therapies.Methods. A medical record search engine was queried to
identify patients diagnosed with PCS from 1992 to 2017 at the University of Michigan. Results. *irty-nine patients with PCS had a
median age of 41 years (range 2–77). Common histologies were angiosarcoma (AS, 14), high-grade undifferentiated pleomorphic
sarcoma (UPS, 10), and leiomyosarcoma (LMS, 5). Sites of origin were left atrium (18), right atrium (16), and pericardium (5). AS was
themost common right-sided tumor; UPS wasmore common on the left. Eighteen patients presented withmetastases involving lung
(10), bone (7), liver (5), and brain (4). Twenty-five patients underwent resection, achieving 3 R0 resections. Patients received amedian
of 2 (1–6) systemic therapies. Median overall survival (OS) was 12.1months (range 0–79). Median OS was 14.0 months and 8.2
months in patients who did or did not undergo resection, respectively (p � 0.018). Brain metastases occurred in 12 (31%) patients, 9
(75%) of whom had left heart tumors, at a median of 8.5months (range 0–75) from diagnosis. Median OS was 5.6months (range
0–30) after the diagnosis of brainmetastases. Conclusions. PCS portends a poor prognosis, because of difficulty in obtaining complete
resection of sarcoma, advanced stage at diagnosis, and high risk of brainmetastases. Providers should be aware of the increased risk of
brain metastases and consider brain imaging at diagnosis and follow-up.
1. Introduction
Primary cardiac tumors are rare, with an overall incidence of
0.001–0.02% [1]. Of these, 25% are malignant, most com-
monly sarcomas. Consequently, the management of patients
with primary cardiac sarcomas (PCSs) is extrapolated from
small case series of afflicted patients and larger series of
patients with sarcomas of different sites of origin but similar
histologic subtypes. PCSs are distinct entities with many
unique features coincident with their site of origin. As tu-
mors are deep, visceral, and involve a critical organ, disease
is often locally advanced impairing resection by the time
symptoms develop.
We present a case series of 39 patients with PCS in
attempt to characterize and better understand disease pre-
sentation, location, treatment modalities, and overall sur-
vival of patients with PCS. We highlight patterns of
metastatic disease, histologic subtypes, and the barriers to
improvements in overall survival of PCS patients.
2. Materials and Methods
2.1. Patient Identification. *e University of Michigan
Electronic Medical Record Search Engine (EMERSE) was
searched using the terms “cardiac sarcoma” and “heart” plus
“sarcoma” to identify patients with a diagnosis of primary
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cardiac sarcoma treated at our institution between 1992 and
2017. Patients with sarcomas originating within the pul-
monary vasculature or great vessels were not included in this
analysis. Details regarding demographics, clinical pre-
sentation, pathologic features, treatment protocols, and
outcome were extracted from clinical records. All research
was approved by the University of Michigan Institutional
Review Board (HUM00068553).
2.2. Statistical Analysis. Descriptive statistics, such as me-
dian and range, were calculated for continuous variables,
and frequencies were presented for categorical variables. To
compare two categorical variables, a frequency table was
created and analyzed using the chi-squared test or Fisher’s
exact test. Overall survival (OS) was estimated by the
Kaplan–Meier method and compared using the log-rank
test. Statistical significance was defined as a two-sided p
value <0.05. All analyses were conducted using SAS (version
9.4, SAS Institute, Cary, NC).
3. Results
3.1. Demographics and Disease Characteristics.
*irty-nine patients with PCS presenting to the University of
Michigan between 1992 and 2017 were identified. Median
age at diagnosis was 41 years. Patient demographics and brief
outline of disease characteristics are summarized in Table 1.
*e most common site of origin was the left heart.
All patients were symptomatic at time of diagnosis, most
frequently with dyspnea (n � 29), chest pain (n � 8), cough
(n � 3), bilateral lower extremity edema (n � 3), and he-
moptysis (n � 3). Twenty patients had evidence of peri-
cardial effusion at diagnosis, including all 5 patients with
pericardial tumors and 11/16 patients with right-sided tu-
mors. Twelve patients had evidence of tamponade at di-
agnosis, one of which had a left atrium (LA) tumor, 8 had
right atrium (RA) tumors, and 3 had pericardial tumors.
Eight patients had pulmonary hypertension at time of di-
agnosis. *ere were no clinically significant arrhythmias
present at diagnosis.
Angiosarcoma was the most common tumor histology
and was more commonly located on the right side of the
heart (n � 11) and pericardium (n � 2, p< 0.0001) com-
pared to other histologies. UPS (n � 8) and LMS (n � 4)
were the most commonly observed left-sided tumors
(Figure 1).
3.2. Metastases. Metastatic disease was present in 18/39
(46%) of PCS patients at the time of diagnosis. *e distri-
bution of metastases at the time of disease diagnosis is listed
in Table 1.
Twelve patients developed brain metastases, 4 of whom
had brain metastases at initial diagnosis. All presented with
neurologic symptoms. Median time from diagnosis of PCS
to diagnosis of brain metastases was 8.5months (range 0–
75.8months). Left-sided cardiac tumors were more com-
monly associated with brain metastases (9/12, p � 0.01)
compared to right-sided and pericardial tumors. *e most
common histological variant was UPS (n � 6). Other his-
tological types included angiosarcoma (3), leiomyosarcoma
(2), and fibrosarcoma (1). All patients with right-sided tu-
mors and brain metastases at diagnosis (n � 3) also had lung
metastases. One patient had evidence of a right to left shunt
on echocardiogram as detected by a bubble study.
3.3. Surgery. Twenty-five patients (64%) underwent surgical
resection of their PCS. Eleven of the twenty-five (11/25, 44%)
patients had evidence of metastatic disease at diagnosis. An
R0 resection was obtained in only 3 patients (12%), all of
whom had left atrial tumors. Nine patients had R1 resections,
11 patients had R2 resections, and the surgical margin in 2
patients was unknown. Five patients with solitary brain
metastases underwent craniotomy as primary management
of their metastatic disease.
3.4. Radiation 2erapy. In total, 11 patients (26%) received
radiation therapy. *ree patients had radiation to the pri-
mary cardiac tumor, one to alleviate superior vena cava
syndrome and two to optimize clinical status prior to sys-
temic chemotherapy. Eight patients received radiation
therapy to brain metastases (5 whole brain and 3 stereotactic
Table 1: Patient demographics and disease characteristics.
No. of
patients (%)
Male 13 (33)
Female 26 (67)
Median tumor size in cm (range) 6.5 (1.7–16)
Median no. of total chemotherapy regimens 2 (range 1–6)
Primary tumor location
Right heart 16 (41)
Left heart 18 (46)
Pericardium 5 (13)
Histology
Angiosarcoma 14 (36)
High-grade undifferentiated pleomorphic sarcoma 10 (26)
Leiomyosarcoma 5 (13)
Intimal sarcoma 3 (8)
Fibrosarcoma 2 (4)
Other 5 (13)
Metastatic disease present at diagnosis 18 (46)
Sites of metastases
Lung 10 (55)
Bone 7 (39)
Liver 5 (28)
Brain 4 (22)
Pancreas 1 (5)
Adrenal 1 (5)
Treatment
Surgery 25 (58)
R0 3 (12)
R1 9 (36)
R2 11 (44)
Unknown 2 (8)
Chemotherapy 28 (72)
Radiation to cardiac tumor 3 (8)
Median age in years (range) 41 (2–77)
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radiotherapy). Four patients received radiation therapy after
resection of solitary brain metastases. Four patients received
radiation therapy alone for multifocal brain metastases. Two
of these patients received palliative radiation to symptomatic
lesions in the bone and lung.
3.5. Systemic2erapy. Twenty-eight patients (72%) received
chemotherapy, with a median of 2 regimens (range 1–6).
Twenty-one patients (75%) who received chemotherapy had
resection of their primary tumor. Two patients received
neoadjuvant chemotherapy followed by resection, R0, and
R1. Figure 2 shows baseline (a) and posttreatment (b) im-
aging for a patient who received neoadjuvant chemotherapy
with good response, enabling subsequent resection.
Most patients received systemic therapy with palliative
intent. Seventeen patients (61%) received doxorubicin plus
ifosfamide (AI) as first-line therapy with a mean of 5 cycles
(range 0.5–9). Ten patients received gemcitabine and
docetaxel (GT) as first (n � 2) or second-line (n � 8) therapy.
Eight patients received 3 or more lines of therapy. Other
chemotherapy regimens frequently used in any line included
paclitaxel (n � 5), dacarbazine (n � 3), and ifosfamide
(n � 3).
3.6. Survival. *e median OS for patients who underwent
surgery was 14.0months (range 1–79months), compared to
8.2months (range 0–33months; p � 0.02) for patients who
did not (Figure 3(a)). Patients who received chemotherapy
lived longer compared to patients who did not with amedian
OS of 14.0months versus 2.4months, respectively
(p � 0.0001, Figure 3(b)). Median OS for all patients was
12.1months (range 0–79months; Figure 3(c)). *ree pa-
tients were alive at the time of data assessment in October
2017, one diagnosed in 2015 and two diagnosed in 2016
(median follow-up time of 19months). Median time from
diagnosis of brain metastases to death was 5.6months (range
0–30months).
Survival differences were not statistically significant
based on the presence of metastatic disease at diagnosis,
tumor location, or tumor histology because, in part, of our
small sample size.
4. Discussion
We present our single-institution experience with primary
cardiac sarcoma with several notable findings: a high in-
cidence of metastatic disease to the brain as compared to
sarcomas originating in other locations, pattern of meta-
static spread associated with location of sarcoma origin
within the heart, predilection of certain histologies to
originate in the right versus left heart, and association of
multimodality therapy with improved patient survival de-
spite the lack of a standardized treatment approach.
We found brain metastases occurred quickly and fre-
quently in our PCS patients. *irty-one percent (12/39) of
our PCS patients developed brain metastases, compared to
1–8% in noncardiac sarcomas [2–7]. *is is close to the
estimated 10–30% prevalence of brain metastases in all
cancer patients [8]. *e median length of time from di-
agnosis to the development of brain metastases has been
reported to be about 27months in other soft tissue sarcomas
[2, 3, 6, 9, 10]. In our patient cohort, however, the median
time from diagnosis of PCS to brain metastasis was
8.5months (range 0.3–75.8months). *is may be secondary
to the intracardiac location of primary tumors, potentially
providing a more direct conduit from tumor to the brain via
the cardiac outflow tract, particularly in left-sided tumors.
*ere are case reports of brain metastases developing in
patients with angiosarcoma, HGPUS, and leiomyosarcoma
[3–5, 7, 9–16]. In our series, the most common histology to
metastasize to the brain was high-grade undifferentiated
pleomorphic sarcoma (n � 6).
HGUPS
Angiosarcoma
44%
11%6%
6%
11%
22%
Intimal
HG sarcoma
Fibrosarcoma
Leiomyosarcoma
(a)
7%
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FIGURE 1: Primary cardiac histology by tumor location.
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*e prevalence of brain metastases in sarcoma is in-
creasing due to prolonged survival from multimodal ther-
apies that have poor CNS penetration [17, 18]. In our
patients who lived longer than 12months (22 pts), brain
metastases eventually developed in 9 (41%). Median OS for
our patients with brain metastases was 13.6months, with a
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Figure 3: Overall Survival of cardiac sarcoma patients (n � 39). Overall survival was significantly improved with surgical resection of PCS
(a) and chemotherapy administration (b). For all patients (c), median overall survival was 12.1months (range 0–79months). *e dashed
curve represents surgery or chemotherapy and solid curve no intervention.
(a) (b)
Figure 2: Baseline cardiac MRI shows a large, heterogeneous mass in the pericardial space with a large effusion and compression of the left
atrium (a). Neoadjuvant chemotherapy with doxorubicin/ifosfamide ×12 cycles and gemcitabine/docetaxel ×6 cycles resulted in near
complete response (b).
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post-brain metastases median survival of 5.6months. *is is
significantly shorter than reports of brain metastases in
sarcomas of all primary sites, which have a median of
13.9months from diagnosis to development of brain me-
tastases and overall and postmetastasis survival of 15 and
9.2months, respectively [3, 5].
*e management of brain metastases is largely de-
pendent on the number of lesions and patient performance
status. Surgical intervention is considered with solitary
metastases, while radiation therapy is preferred for multi-
focal disease or in patients with marginal performance
status. Metastasectomy of brain metastases is reported to
result in increased post-brain metastases survival to about
9months, compared with 2.7months for those who did not
receive surgical intervention [3]. In our cohort, one patient
underwent metastasectomy alone with a post-brain metas-
tases survival of 12months. In our cohort, 4 patients re-
ceived radiation therapy for brain metastases with a median
post-brain metastases survival of 8months. Four patients
underwent surgical resection followed by radiation with a
post-brain metastases survival of 5.5months. Since most
patients had received chemotherapy by the time they de-
velop brain metastases, the role of chemotherapy in brain
metastases remain unclear [5, 16].
Surgical resection is the preferred management for
localized sarcomas. As compared to other sarcomas, PCS
patients are more likely to have advanced stage or in-
operable primary tumor at presentation. Barriers to
complete resection include anatomic location and de-
clining performance status due to tumor at presentation.
Given the difficulty in achieving complete resection with
cardiac tumors, autotransplantation has been explored to
allow for complete resection and optimal reconstruction.
Ramlawi et al. reported on their institutional experience
with cardiac transplant in 34 patients with left-sided car-
diac tumors [19]. In their series, 26 patients had primary
cardiac sarcomas. In those with malignant tumors, 1- and
2-year survival was 46% and 28%, respectively. While the
authors conclude cardiac autotransplantation to be feasible
and safe for complex left-sided tumors, this should only be
considered in certain individuals and performed at expe-
rienced specialty centers.
Nearly 50% of our patients had evidence of metastatic
disease at time of presentation, which is higher than the
reported 20–30% in several case series [20–23]. In our pa-
tient cohort, metastatic disease at presentation did not
impact survival compared with those with localized disease
(14months versus 10months, p � 0.12, respectively), while
surgical resection did (p � 0.02), highlighting the impor-
tance of local disease control. *is survival benefit of re-
section has been noted in other reports of PCS and is
independent of the presence of metastatic disease [24]. *is
may be due to the preservation of cardiac function as heart
failure has been described as the most common cause of
death of PCS patients [25]. Furthermore, improved cardiac
function ultimately aids in ability to administer systemic
therapy, specifically an anthracycline.
Surgery alone, however, is not enough to prevent pri-
mary tumor recurrence or distant metastases. Most patients
who undergo complete (R0) resections without metastatic
disease will relapse, highlighting the need for systemic
therapy [22, 26]. Although multimodal therapy for PCS
patients is associated with improved survival [20, 21, 26],
the specific role of radiation and chemotherapy alone or in
combination in PCS has yet to be defined. A univariate
analysis by Isambert et al. found that chemotherapy offered
a survival advantage only in patients who did not undergo
primary cardiac tumor resection [24]. Abu Saleh et al.
reviewed the utility of neoadjuvant chemotherapy in the
management of right-sided cardiac tumors in 44 patients
[27]. In their cohort, 73% of patients received neoadjuvant
chemotherapy consisting of doxorubicin and ifosfamide.
*ere was a significant improvement in median overall
survival in patients who achieved a complete (R0) versus R1
resection, 53.5months and 9.5months, and those who
received neoadjuvant chemotherapy versus primary sur-
gery, 20 versus 9.5months, respectively. *e authors
conclude that neoadjuvant chemotherapy improves the
ability to achieve complete resection and thus translates
into improved survival. However, the ability to deliver
neoadjuvant chemotherapy relies on accurate preresection
diagnosis. Given the rarity of these tumors and clear
benefits to multimodality therapies, it is imperative to
employ a multidisciplinary team approach. *e creation of
a multispecialty, multi-institution cardiac tumor board in
which our institution participates enhances the ability for
cross-discipline discussions to optimally manage these
challenging tumors.
In our patient cohort, those who received chemo-
therapy alone and those who underwent surgical resection
and received systemic chemotherapy had a survival ad-
vantage (p � 0.039) compared to those who did not receive
chemotherapy. Given the retrospective nature of this
study, it is important to note that patients who receive
chemotherapy generally have better performance status
and organ function, which likely impacted the survival
advantage noted with chemotherapy. Local disease con-
trol, resulting in improved cardiac function, likely results
in better performance status and ability to tolerate ag-
gressive therapies.
5. Conclusions
Primary cardiac sarcomas are rare, confer increased risk of
brain metastases, are associated with shorter survival du-
ration, and have a higher disease-specific mortality com-
pared to soft tissue sarcomas arising in extracardiac sites.
Increased mortality may be due to the difficulty with
complete resection and high disease and symptom burden at
presentation, making aggressive multimodal therapy diffi-
cult. Multidisciplinary care incorporating surgery, radiation,
and systemic therapy when appropriate constitutes ideal
management. Based on our findings, we recommend brain
imaging at the time of primary cardiac sarcoma diagnosis
given the incidence of brain metastases. Furthermore, our
results suggest a role for aggressive multimodal therapy
including resection and systemic therapy, even in the
metastatic setting, to improve outcomes.
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